Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CureVac N.V (CVAC) Cash & Equivalents: 2019-2025

Historic Cash & Equivalents for CureVac N.V (CVAC) over the last 4 years, with Jun 2025 value amounting to $444.5 million.

  • CureVac N.V's Cash & Equivalents rose 103.83% to $444.5 million in Q2 2025 from the same period last year, while for Jun 2025 it was $444.5 million, marking a year-over-year increase of 103.83%. This contributed to the annual value of $514.8 million for FY2024, which is 18.89% up from last year.
  • As of Q2 2025, CureVac N.V's Cash & Equivalents stood at $444.5 million, which was down 3.59% from $461.1 million recorded in Q1 2025.
  • Over the past 5 years, CureVac N.V's Cash & Equivalents peaked at $1,632.8 billion during Q2 2021, and registered a low of $218.1 million during Q2 2024.
  • Its 3-year average for Cash & Equivalents is $475.6 million, with a median of $483.2 million in 2023.
  • As far as peak fluctuations go, CureVac N.V's Cash & Equivalents surged by 119,930.74% in 2021, and later plummeted by 99.96% in 2022.
  • Quarterly analysis of 5 years shows CureVac N.V's Cash & Equivalents stood at $928.3 million in 2021, then crashed by 45.51% to $505.8 million in 2022, then decreased by 14.40% to $433.0 million in 2023, then increased by 18.89% to $514.8 million in 2024, then skyrocketed by 103.83% to $444.5 million in 2025.
  • Its Cash & Equivalents was $444.5 million in Q2 2025, compared to $461.1 million in Q1 2025 and $514.8 million in Q4 2024.